ライフサイエンスコーパス: saphenous

1 to facilitate placement of sutureless aorto-saphenous anastomoses during off-pump coronary artery by

2 ression through Rho-kinase, we exposed human saphenous and pulmonary artery endothelial cells to hypo

3 mean caliber of myelinated axons in both the saphenous and sciatic nerves was reduced in galactose-in

4 In the largely cutaneous saphenous and sural nerves, the naked mole-rat had the l

5 d mouse skeletal muscle arterioles and mouse saphenous arteries were isolated, pressurized, and subje

6 (gAd) and insulin on pre-constricted distal saphenous arteries.

7 s 30% for popliteal arteries, 45% vs 28% for saphenous arteries; P < .001 for both comparisons) and e

8 eparin to inhibit intimal hyperplasia in the saphenous artery of the baboon after balloon angioplasty

9 n tension were determined in isolated distal saphenous artery.

10 in penile cancer and the Nesbit operation or saphenous grafting for Peyronie's disease.

11 usion or significant stenoses of preexisting saphenous grafts were thought to be the major cause of r

12 patients (3.51%) (25.1% mediastinitis, 32.6% saphenous harvest site, 35.0% septicemia, 0.5% thoracoto

13 CN), left dorsal collector nerve (DCN), left saphenous nerve (SN) or left renal nerve (RN).

14 in myelinated axons in the mid-shaft of the saphenous nerve and in the sensory ganglion cells.

15 nd hairy hindpaw skin at various times after saphenous nerve axotomy suggested multiple changes in ne

16 reventing movement-induced afferent input by saphenous nerve block before, but not after, hindlimb mo

17 cancer learn to prefer a context paired with saphenous nerve block to elicit pain relief (i.e., condi

18 ment with systemic morphine abolished CPP to saphenous nerve block, demonstrating control of ongoing

19 Injection of Sox11 siRNAs into the mouse saphenous nerve caused a transient knockdown of Sox11 mR

20 ation of capsaicin to skin innervated by the saphenous nerve increased mitochondrial traffic in both

21 tron microscopy, we recently showed that the saphenous nerve of the naked mole-rat (Heterocephalus gl

22 llular recordings of single neurons from the saphenous nerve of vincristine-treated rats.

23 r units were not evenly distributed over the saphenous nerve receptive field.

24 ive C fibres was evenly distributed over the saphenous nerve receptive field.

25 s of hairy hindpaw skin and L2/L3 DRGs after saphenous nerve regeneration suggested that inhibition o

26 nges in mouse cutaneous CH neurons following saphenous nerve regeneration.

27 We have shown recently that following saphenous nerve transection and successful regeneration,

28 ctional class of afferent C fibre in the rat saphenous nerve, and are not found in the rabbit sapheno

29 rs after transection and regeneration of the saphenous nerve.

30 enous nerve, and are not found in the rabbit saphenous nerve.

31 Saphenous nerves and spinal roots of anaesthetized trans

32 ive adult axons in vivo, confocal imaging of saphenous nerves in anaesthetised mice was combined with

33 eralgesia, we analyzed unmyelinated axons in saphenous nerves of vincristine-treated rats.

34 ed in the galactose group, while sciatic and saphenous sensory NCVs were not significantly changed.

35 d 20 and 16% reductions in sciatic motor and saphenous sensory nerve conduction velocity, which were

36 ammary artery (6.2+/-0.3 pmol/mg protein) or saphenous vein (1.4+/-0.2 pmol/mg protein, both P<0.05).

37 ammary artery (3.5+/-1.3 pmol/mg protein) or saphenous vein (1.4+/-0.3 pmol/mg protein, both P<0.0001

38 er than internal mammary artery (56+/-9%) or saphenous vein (11+/-5%, both P<0.0001).

39 %) than internal mammary artery (23+/-6%) or saphenous vein (5+/-2%, both P<0.05).

40 internal mammary artery (203+/-32 nmol/L) or saphenous vein (97+/-12 nmol/L, both P<0.05).

41 cantly augmented BH4 levels in plasma and in saphenous vein (but not internal mammary artery) but als

42 utive patients with primary unilateral great saphenous vein (GSV) reflux undergoing endovenous treatm

43 Standard harvest and preparation of human saphenous vein (HSV) for autologous coronary and periphe

44 ue with a cumulative manner in ex vivo human saphenous vein (HSV) model.

45 n macrovascular endothelial cells from human saphenous vein (HSVEC).

46 ion of endothelial cells cultured from human saphenous vein (HSVECs) has identified a voltage-gated N

47 cation to the carotid artery (high shear) or saphenous vein (lower shear); hyperfibrinogenemia signif

48 mutation in FOXC2 showed reflux in the great saphenous vein (n=18), compared with only 1 of 12 refere

49 radial artery, internal mammary artery, and saphenous vein (n=24 patients) were examined by use of o

50 , and venous surgery not involving the great saphenous vein (OR = 15.61, P < 0.001).

51 - 0.2% for the RA, and 55.0 +/- 0.2% for the saphenous vein (p = 0.002 for RA vs. saphenous vein, 0.1

52 trial comparing treatment options for small saphenous vein (SSV) incompetence exists, and there is n

53 trial comparing treatment options for small saphenous vein (SSV) incompetence exists, and there is n

54 on is associated with intimal hyperplasia in saphenous vein (SV) bypass grafts.

55 operation: 2,389 had LITA grafting and 1,084 saphenous vein (SV) grafting to the LAD.

56 have significantly better patency rates than saphenous vein (SV) grafts at 5 years, but the physiolog

57 y artery, internal mammary artery (IMA), and saphenous vein (SV).

58 profiles of primary cultured ECs from human saphenous vein (SVEC) and coronary artery (CAEC) exposed

59 that this axis behaves the same as the great saphenous vein after treatment.

60 that this axis behaves the same as the great saphenous vein after treatment.

61 reas internalization in large vessel EC from saphenous vein and aorta is rapid, like HUVEC.

62 Segments of saphenous vein and internal mammary artery and confluent

63 ynthase (eNOS) uncoupling were quantified in saphenous vein and internal mammary artery segments.

64 ivo release were quantified in perivascular (saphenous vein and internal mammary artery) subcutaneous

65 ent human smooth muscle cells, cultured from saphenous vein and internal mammary artery, were exposed

66 eceptors were shown to be expressed in human saphenous vein and internal mammary artery.

67 nd BH4 levels were determined in segments of saphenous vein and internal mammary artery.

68 imately 90% and 50% of cells in intact human saphenous vein and rat myocardium, respectively.

69 d during stenting in 22 patients with severe saphenous vein aorto-coronary bypass stenoses.

70 he angiographic patency of radial artery and saphenous vein aortocoronary bypass grafts at 5 years af

71 bosis, which is the final common pathway for saphenous vein arterial bypass graft occlusion.

72 rimary, isolated CABG with the LITA, RA, and saphenous vein as needed.

73 nous enhancement (99 HU) was observed in the saphenous vein at the ankle, with all other venous stati

74 Here, we use the saphenous vein bleeding model to compare the efficacy of

75 The use of aortic connectors for proximal saphenous vein bypass graft anastomoses eliminates the n

76 utaneous revascularization (PCI) of diseased saphenous vein bypass grafts (SVGs).

77 At angiography, 20 saphenous vein bypass grafts containing 19 connectors we

78 els and studies in patients (coronary artery saphenous vein bypass grafts, lesions of restenosis afte

79 me has been disappointing so far, except for saphenous vein bypass grafts.

80 ase as the quest for an alternative graft to saphenous vein continues.

81 Results from a functional assay (rabbit saphenous vein contraction) demonstrate that certain dim

82 Autologous saphenous vein coronary artery bypass graft surgery is c

83 that may prevent early and late occlusion of saphenous vein coronary bypass conduits.

84 complications during stenting of degenerated saphenous vein coronary bypass grafts are reduced, but n

85 nstable angina, peripheral arterial disease, saphenous vein coronary bypass grafts, and diabetic reti

86 ine the effects of MARCKS silencing in human saphenous vein cultured ex vivo.

87 Primary cultures of human saphenous vein endothelial cells (ECs) and vascular smoo

88 ere incubated with IFN-gamma-activated human saphenous vein endothelial cells (HSVEC), but not with r

89 in bovine aortic endothelial cells and human saphenous vein endothelial cells in vitro and in adult m

90 to human erythroleukemia cells and to human saphenous vein endothelial cells was mediated by both al

91 Human saphenous vein endothelial cells were treated with ox-LD

92 ls of the hH1 isoform are expressed in human saphenous vein endothelium and that the presence of thes

93 In saphenous vein endothelium exposed to arterial flow cond

94 tion suppressed vascular remodeling of human saphenous vein explants ex vivo.

95 Segments of internal mammary artery and saphenous vein from patients undergoing coronary artery

96 ve resulted in more favorable outcomes after saphenous vein graft (SVG) angioplasty.

97 stent implantation versus stenting alone for saphenous vein graft (SVG) aortoostial lesions.

98 The pattern of saphenous vein graft (SVG) calcification before percutan

99 aft on long-term outcomes after percutaneous saphenous vein graft (SVG) intervention is currently unk

100 t of creatine kinase (CK-MB) elevation after saphenous vein graft (SVG) intervention is high, its pro

101 use of embolic protection devices (EPD) for saphenous vein graft (SVG) intervention; however, studie

102 We sought to examine saphenous vein graft (SVG) lesions that fail within the

103 sealing intermediate nonobstructive coronary saphenous vein graft (SVG) lesions with drug-eluting ste

104 PES) and a similar bare-metal stent (BMS) in saphenous vein graft (SVG) lesions.

105 et effect of aspirin, or both, contribute to saphenous vein graft (SVG) occlusion after coronary arte

106 pose of this study was to present radial and saphenous vein graft (SVG) occlusion results more than 5

107 assess disease progression in nonintervened saphenous vein graft (SVG) segments to determine the nat

108 Treatment of saphenous vein graft (SVG) stenosis with percutaneous co

109 ectiveness of gamma-irradiation ((192)Ir) in saphenous vein graft (SVG) versus native coronary artery

110 20%) also received an RA graft instead of a saphenous vein graft (SVG).

111 cutaneous coronary intervention (PCI) of the saphenous vein graft (SVG).

112 25 women) underwent stenting of 212 vessels (saphenous vein graft [53%], left anterior descending cor

113 ) or conventional treatment (n = 395) in the Saphenous Vein Graft Angioplasty Free of Emboli Randomiz

114 Saphenous vein graft angioplasty has been limited by hig

115 ient and SVG characteristics associated with saphenous vein graft atherosclerosis progression.

116 Angiographic changes in saphenous vein graft conduits 4.3 years after entry were

117 lower FitzGibbon A patency for arterial and saphenous vein graft conduits and less effective revascu

118 bolysis in 39%, cardiogenic shock in 17% and saphenous vein graft culprit in 11% of patients.

119 e use of a radial artery graft compared with saphenous vein graft did not result in greater 1-year pa

120 sis, bifurcation lesions, left main disease, saphenous vein graft disease, and acute coronary syndrom

121 ve coronary arteries, inhibit the process of saphenous vein graft disease, and improve vein graft pat

122 Aortocoronary saphenous vein graft disease, with its increasing clinic

123 tionship may also be seen after treatment of saphenous vein graft disease.

124 feration of the intima is an early lesion of saphenous vein graft disease.

125 High success was achieved in the saphenous vein graft group.

126 The Protection During Saphenous Vein Graft Intervention to Prevent Distal Embo

127 When saphenous vein graft interventions were excluded, howeve

128 During saphenous vein graft interventions, particulate retrieve

129 essels, long coronary stenoses, and possibly saphenous vein graft interventions.

130 omes of embolic protection devices (EPDs) in saphenous vein graft interventions.

131 ative coronary artery stenoses (CAVEAT-I) or saphenous vein graft lesions (CAVEAT-II) were randomized

132 undergoing percutaneous intervention of 682 saphenous vein graft lesions were prospectively randomiz

133 ocation (78.6% in left main lesion, 69.7% in saphenous vein graft lesions, 42.4% in circumflex lesion

134 We recently demonstrated in a pig saphenous vein graft model that application of an extern

135 In patients undergoing DCA or PTCA of saphenous vein graft narrowings, the relationship betwee

136 h platelet activation (deep vein thrombosis; saphenous vein graft occlusion after coronary bypass sur

137 In contrast, saphenous vein graft patency declined over time and simi

138 eft internal mammary artery), reperfusion B (saphenous vein graft perfusion).

139 Saphenous vein graft stenosis is a significant clinical

140 uardWire balloon or a vascular filter during saphenous vein graft stenting.

141 epeat revascularization than did multivessel saphenous vein graft stenting.

142 otection filter devices during uncomplicated saphenous vein graft, carotid, renal, and superficial fe

143 ere administered into the coronary artery or saphenous vein graft.

144 hen the infarct-related vessel is a diseased saphenous vein graft.

145 of retrograde CTO PCI via patent or occluded saphenous vein graft.

146 nt vessel was randomized to radial artery vs saphenous vein graft.

147 e center to have either the radial artery or saphenous vein grafted to a stenosed branch of the nativ

148 of patients undergoing a nonstaged multiple saphenous vein grafting (SVG) intervention with stents a

149 rteries (38.5%) and greater than that in new saphenous vein grafts (11.8%).

150 at the feasibility and safety of CTO PCI via saphenous vein grafts (19% of post-CABG cases) versus co

151 ternal mammary arteries (90.3%, P<0.0001) or saphenous vein grafts (64.0%, P=0.0016).

152 l conduits (85.8% versus 91.4%; P=0.003) and saphenous vein grafts (72.7% versus 80.4%; P<0.001).

153 ernal thoracic artery (LITA) supplemented by saphenous vein grafts (LITA+SVG) has been demonstrated i

154 EPDs were used in 21.2% of saphenous vein grafts (median age, 75; 23% women) and we

155 enosis rate of 15.1%, compared with 5.9% for saphenous vein grafts (P=0.0003) and 4.8% for left inter

156 atent radial artery grafts and 23% of patent saphenous vein grafts (P=0.01).

157 ception of patients treated with degenerated saphenous vein grafts (risk with placebo 16.3% vs. risk

158 This study defined long-term patency of saphenous vein grafts (SVG) and internal mammary artery

159 l outcome after percutaneous intervention of saphenous vein grafts (SVG) and to identify the predicto

160 iabetic patients after stent implantation in saphenous vein grafts (SVG).

161 S) for percutaneous coronary intervention in saphenous vein grafts (SVG).

162 Stenosis of saphenous vein grafts (SVGs) after coronary artery bypas

163 tomy prior to stent implantation in diseased saphenous vein grafts (SVGs) and thrombus-containing nat

164 Saphenous vein grafts (SVGs) are effective in relieving

165 Intimal hyperplasia of saphenous vein grafts (SVGs) can lead to subsequent graf

166 Because saphenous vein grafts (SVGs) exhibit greater cellular he

167 Percutaneous coronary intervention (PCI) of saphenous vein grafts (SVGs) has historically been assoc

168 In each patient, all saphenous vein grafts (SVGs) placed (n = 11) with the de

169 Aortocoronary saphenous vein grafts (SVGs) undergo structural changes

170 s related to successful stenting of diseased saphenous vein grafts (SVGs) using a novel filter-based

171 ercutaneous coronary interventions (PCIs) in saphenous vein grafts (SVGs) with thrombus have a high f

172 coronary interventions (PCIs) in degenerated saphenous vein grafts (SVGs) without distal embolic prot

173 before CABG would improve the redox state in saphenous vein grafts (SVGs), independently of low-densi

174 ruptured atherosclerotic plaques detected in saphenous vein grafts (SVGs).

175 ffects, is expressed in "arterialized" human saphenous vein grafts (SVGs).

176 of a high risk cohort treated with stents in saphenous vein grafts (SVGs).

177 gnificantly better than the patency rate for saphenous vein grafts and comparable to reported patency

178 er superior long-term survival compared with saphenous vein grafts and should be considered in patien

179 erosclerotic progression among patients with saphenous vein grafts and that aggressive lipid lowering

180 nct to percutaneous intervention of diseased saphenous vein grafts and, compared with distal protecti

181 Saphenous vein grafts are exposed to hemodynamic stress

182 To achieve high success rate, use of saphenous vein grafts as retrograde conduits seems to be

183 nary stenting of stenoses in old (> 9 years) saphenous vein grafts can be successfully performed, wit

184 rafts are thought to be better conduits than saphenous vein grafts for coronary artery bypass graftin

185 The PercuSurge GuardWire was used in 17 saphenous vein grafts in 16 patients.

186 istal pore size 100 microns) were used in 47 saphenous vein grafts in 44 patients.

187 after percutaneous intervention in diseased saphenous vein grafts is reduced by distal microcirculat

188 placebo on progression of atherosclerosis in saphenous vein grafts of patients who had had CABG surge

189 placebo on progression of atherosclerosis in saphenous vein grafts of patients who had had CABG surge

190 Interventions were performed on either saphenous vein grafts or native vessels and utilized ang

191 enever possible during treatment of diseased saphenous vein grafts produced outcomes similar to those

192 Implantation of saphenous vein grafts promotes upregulation of NADPH oxi

193 Saphenous vein grafts remain patent for approximately 10

194 rates of drug-eluting stents, which outlive saphenous vein grafts to non-left anterior descending ve

195 Medical) was developed to rapidly anastomose saphenous vein grafts to the aorta during coronary bypas

196 Saphenous vein grafts used in coronary artery bypass gra

197 ; 98.3% of radial artery grafts and 86.4% of saphenous vein grafts were patent (P=0.04).

198 l of 594 patients undergoing stenting of 639 saphenous vein grafts were prospectively randomized, usi

199 Early and late patency of saphenous vein grafts were similar in patients with and

200 year clinical outcomes of patients receiving saphenous vein grafts with multiple (m-SVG) versus singl

201 ger vessels, in the right coronary artery or saphenous vein grafts, and for unfavorable lesion charac

202 xus and Cardiac Surgery) score, treatment of saphenous vein grafts, ostial lesions, and in-stent rest

203 anterior descending, right coronary artery, saphenous vein grafts, ostial lesions, or in-stent reste

204 ncy has been shown to be superior to that of saphenous vein grafts.

205 rates than left internal mammary artery and saphenous vein grafts.

206 reased the progression of atherosclerosis in saphenous vein grafts.

207 in-stent restenosis in native coronaries and saphenous vein grafts.

208 ors for a rapid atherosclerotic attrition of saphenous vein grafts.

209 the detrimental effect of atherosclerosis on saphenous vein grafts.

210 n may reduce the risk of early thrombosis in saphenous vein grafts.

211 rnal thoracic artery (ITA) grafts and 20,066 saphenous vein grafts.

212 , or ostial; total occlusions; bifurcations; saphenous vein grafts; and multivessel interventions) fr

213 up reported significantly more pain than the saphenous vein group 3 months after surgery; however, si

214 (366 in the radial artery group, 367 in the saphenous vein group).

215 operative baseline between radial artery and saphenous vein groups after adjusting for covariates (P

216 e consequences of radial artery harvest with saphenous vein harvest in patients undergoing elective c

217 hundred forty-two patients with sternal and saphenous vein harvest wounds had half of each wound clo

218 Use of endoscopic saphenous vein harvesting has developed into a routine s

219 The human saphenous vein has a greater propensity for intimal hype

220 function in normal and atherosclerotic human saphenous vein imply a role for the peptide in the progr

221 Using human saphenous vein in a validated ex vivo flow circuit, we i

222 ides superior long-term patency rates to the saphenous vein in most situations.

223 reduced the average time to hemostasis after saphenous vein incision, and the time to occlusion after

224 ure base, centered on the treatment of great saphenous vein incompetence cannot simply be extrapolate

225 the time to occlusion after FeCl(3)-induced saphenous vein injury.

226 was to assess thrombus age in patients with saphenous vein insufficiency treated with sclerotherapy.

227 f stenotic coronary arteries with autologous saphenous vein is an established treatment for ischemic

228 Similar effects were observed in human saphenous vein medial segments where proliferation was r

229 F-positive MPs had increased thrombosis in a saphenous vein model.

230 analysis had radial artery only (n = 80) or saphenous vein only (n = 337) harvest.

231 atients enrolled in the Radial artery versus Saphenous Vein Patency (RSVP) trial.

232 recipients: 3 of 3 organ recipients, 1 of 2 saphenous vein recipients, 1 of 3 tendon recipients, and

233 ility was evaluated by organ bath studies on saphenous vein rings.

234 rior descending artery, and radial artery or saphenous vein segments are used to graft the lateral an

235 l artery in vivo and by vasomotor studies in saphenous vein segments ex vivo.

236 nical significance was investigated by using saphenous vein segments from non-coronary heart disease

237 At operation, saphenous vein segments were explanted for VSMC culture.

238 growth factor-stimulated migration of human saphenous vein SMCs and decrease phosphorylation of the

239 tudy, transient transfection assays in human saphenous vein smooth muscle cells (HSVSMC) and pulmonar

240 od or from adult peripheral blood, and human saphenous vein smooth muscle cells (HSVSMCs) as a source

241 n was increased in carotid atherectomies and saphenous vein specimens from diabetic versus nondiabeti

242 diabetic and nonischemic patients undergoing saphenous vein stripping were used.

243 Exposure of VSMCs derived from human saphenous vein to C pneumoniae EBs (3x10(7) inclusion fo

244 ncRNAs whose expression was altered in human saphenous vein vascular smooth muscle cells following st

245 -derived growth factor-BB (PDGF-BB) in human saphenous vein VSMCs.

246 uccessful ablation of the main trunks of the saphenous vein was less common in the foam group than in

247 Harvested segments of human saphenous vein were exposed for 1 hour at 37 degrees C t

248 Segments of internal mammary artery and saphenous vein were obtained during coronary artery bypa

249 nts, segments of internal mammary artery and saphenous vein were obtained from five patients who rece

250 = 65 years) in mammary artery (no change in saphenous vein), accompanied by increased alpha(1b)>alph

251 11 for RA vs. ITA, and p < 0.001 for ITA vs. saphenous vein).

252 for the saphenous vein (p = 0.002 for RA vs. saphenous vein, 0.11 for RA vs. ITA, and p < 0.001 for I

253 89%; 95% confidence interval [CI], 86%-93%; saphenous vein, 239/269; 89%; 95% CI, 85%-93%; adjusted

254 ments from either internal mammary artery or saphenous vein, both forskolin and 8-Br-cAMP inhibited l

255 reduced the adhesion of these cells to human saphenous vein, whereas PBM adhesion in the presence of

256 Adaptation of saphenous vein, with its intrinsic myogenic tone, from t

257 Compare the reparative potential of saphenous vein-derived pericytes (SVPs) with that of car

258 MT1-MMP expression in human saphenous vein-derived smooth muscle cells (SMCs) mainta

259 duced neointimal formation in cultured human saphenous vein.

260 m aortic and coronary artery, as well as the saphenous vein.

261 panel graft constructed of recipient greater saphenous vein.

262 to those of the internal mammary artery and saphenous vein.

263 hich all others are compared--is the greater saphenous vein.

264 g-term patency of this conduit compared with saphenous vein.

265 ater than that of internal mammary artery or saphenous vein.

266 e was obtained with smooth muscle cells from saphenous vein.

267 reoperation over single thoracic artery with saphenous vein.

268 smooth muscle cells were cultured from human saphenous vein.

269 easured by thromboelastography and prolonged saphenous-vein bleeding times, which are consistent with

270 tion in patients with in-stent restenosis of saphenous-vein bypass grafts.

271 Treatment of stenosis in saphenous-vein grafts after coronary-artery bypass surge

272 of 120 patients with in-stent restenosis in saphenous-vein grafts, the majority of whom had diffuse

273 omes in patients with obstructive disease of saphenous-vein grafts.

274 number of arterial grafts into the LIMA plus saphenous veins (LIMA/SV) group (n=7435) or the MultArt

275 s of culture, the I/M ratio increased in the saphenous veins (P=0.03, P=0.04 versus 0 day, respective

276 Internal mammary arteries (IMAs) and saphenous veins (SVs) were collected at the time of card

277 tylcholine and bradykinin were determined in saphenous veins and internal mammary arteries from 117 p

278 superoxide production was quantified in both saphenous veins and internal mammary arteries from 45 di

279 F, and total homocysteine were determined in saphenous veins and internal mammary arteries obtained d

280 Samples of saphenous veins and internal mammary arteries were colle

281 sma and vascular biopterins (P<0.05 for both saphenous veins and internal mammary arteries).

282 In ex vivo experiments with human saphenous veins and internal mammary arteries, adiponect

283 henous veins before organ culture and in pig saphenous veins before interposition grafting into carot

284 essed TIMP-3 at the luminal surface of human saphenous veins before organ culture and in pig saphenou

285 We determined whether human saphenous veins can be transduced with adenovirus vector

286 Limitations in the long-term patency of saphenous veins for bypass grafts have encouraged intere

287 factor (VWF) by immunofluorescence in great saphenous veins harvested at cardiac bypass surgery.

288 P)H oxidase activity was determined in human saphenous veins obtained from 110 patients with coronary

289 peroxide production were determined in human saphenous veins obtained from 133 patients with coronary

290 Adenovirus-mediated gene transfer to human saphenous veins resulted in functional transgene express

291 nsfers to inhibit intimal hyperplasia in the saphenous veins was evaluated.

292 3.8+/-0.8% in the internal mammary arteries, saphenous veins, and normal coronary arteries, respectiv

293 istance arteries, internal mammary arteries, saphenous veins, and small subcutaneous veins were studi

294 f 100 sternotomy CABG patients using IMA and saphenous veins, both treating equivalent number of targ

295 l of intimal hyperplasia, we incubated human saphenous veins, internal mammary arteries, and radial a

296 In ex vivo experiments with human saphenous veins/internal mammary arteries and adipose ti

297 -C protein was not detected in control human saphenous veins; however, it was uniformly and strongly

298 nts provide effective treatment for stenotic saphenous venous aorto-coronary bypass grafts, but their

299 mal proliferation, sclerosis of arterialized saphenous venous graft, and fibromuscular dysplasia) rev

300 embolic protection group during treatment of saphenous venous grafts (SVGs).